IDWeek Highlights |Dr. Mei Zeng: Racing Against Time! Developing the Predictive Models for Early Identification of Severe Infections in Newborns

IDWeek Highlights |Dr. Mei Zeng: Racing Against Time! Developing the Predictive Models for Early Identification of Severe Infections in Newborns

Half of all global child deaths under the age of 5 are caused by infections, and half of all sepsis patients worldwide are children, especially newborns. These alarming statistics highlight the significant challenge of infection treatment in pediatric clinical practice. At the recent IDWeek 2023 congress in the United States, a predictive model for severe infection in infants under 90 days of age, based on clinical data and inflammatory biomarkers, was reported. This predictive model may aid in the early identification of newborns at high risk of severe infection, allowing timely clinical intervention to reduce the risk of disease progression. Dr. Mei Zeng from the Children's Hospital of Fudan University/National Children's Medical Center provides an introduction and commentary on this research.
IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

Precision treatment starts with accurate diagnosis. The clinical diagnosis of ventilator-associated pneumonia (VAP) is challenging, with a high misdiagnosis rate leading to excessive antibiotic use. At the recent 2023 IDWeek conference in the United States, a clinical trial was reported that utilized a bundled approach to VAP diagnosis and management. The results showed that it is safe and significantly reduces the respiratory culture positivity rate and antibiotic usage. Below, Professor Wang Yimin and his team from the China-Japan Friendship Hospital introduce and comment on this study.
Dr. Chun-hui Li’s Commentary on a Randomized Controlled Trial of Oral Fosfomycin for Down-Step Therapy in ESBL-E Complicated Urinary Tract Infections

Dr. Chun-hui Li’s Commentary on a Randomized Controlled Trial of Oral Fosfomycin for Down-Step Therapy in ESBL-E Complicated Urinary Tract Infections

Carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have been designated as "urgent priorities" in antibiotic research and development by the WHO. Besides accelerating the development of new drugs, emphasizing the "repurposing" of existing drugs under antimicrobial stewardship (AMS) can help alleviate the threat of resistant bacteria. At the 2023 IDWeek congress, There is a study using oral fosfomycin as a step-down therapy for ESBL-E complicated urinary tract infections (cUTI), as an alternative to intravenous beta-lactam/beta-lactamase inhibitor (BL/BLIS) therapy, achieving non-inferiority results. Dr. Chun-hui Li from Xiangya Hospital, Central South University, introduces and comments on the study as follows.
IDWeek Highlights | Dr. Yi Shi  Comments on a Single-Center Cohort Study of Colistin Therapy for CRAB Pneumonia

IDWeek Highlights | Dr. Yi Shi  Comments on a Single-Center Cohort Study of Colistin Therapy for CRAB Pneumonia

Carbapenem-resistant Acinetobacter baumannii (CRAB) infection is considered one of the most challenging issues among carbapenem-resistant gram-negative bacteria (CRO) due to limited effective treatment options. Colistin, a polymyxin antibiotic used for "repurposing" in the treatment of CRAB, is one of the few choices available in China. A recent presentation at the 2023 IDWeek congress reported findings from a single-center cohort study conducted in South Korea, suggesting that colistin therapy for CRAB pneumonia lacks efficacy and is associated with an increased incidence of acute kidney injury (AKI) [1]. Dr. Yi Shi from Jinling Hospital, Nanjing University School of Medicine, provides an introduction and commentary on this study below.
IDweek2023 | Antimicrobial Utilization in Transplant Patients: A Deep Dive into Benchmarked Data

IDweek2023 | Antimicrobial Utilization in Transplant Patients: A Deep Dive into Benchmarked Data

IDweek2023 Antimicrobial Utilization in Transplant Patients: A Deep Dive into Benchmarked Data Transplant patients, encompassing those who undergo bone marrow transplants (BMT), allogeneic transplants, autologous transplants, and CAR-T procedures, represent a particularly vulnerable subgroup of the population because of their immunocompromised status. The medical management of these patients involves careful monitoring and appropriate utilization of antimicrobial agents to prevent potential infections and ensure optimal health outcomes.
IDweek2023 | A Comprehensive Examination of Racial, Ethnic, and Gender Disparities in Sepsis Treatment and Outcomes

IDweek2023 | A Comprehensive Examination of Racial, Ethnic, and Gender Disparities in Sepsis Treatment and Outcomes

IDweek2023 A Comprehensive Examination of Racial, Ethnic, and Gender Disparities in Sepsis Treatment and Outcomes Sepsis, an extreme response to infection that can lead to life-threatening organ dysfunction, poses a significant global health issue. Despite advancements in healthcare, disparities in the treatment and outcomes of sepsis persist, particularly in relation to race, ethnicity, and gender. This article aims to shed light on these disparities, explore the potential underlying causes, and discuss the implications for healthcare providers and patients.
IDweek2023 | A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

IDweek2023 | A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals